Global Viral Vector Manufacturing Market Driven by Advancements in Gene and Cell Therapies

Mordor Intelligence has published a new report on the Global Viral Vector Manufacturing Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The Global Viral Vector Manufacturing Market is estimated to reach USD 2.95 billion in 2025 and is expected to grow to USD 7.66 billion by 2030, with a compound annual growth rate (CAGR) of 21.01% over the forecast period from 2025 to 2030. The increasing prevalence of genetic disorders, cancer, and infectious diseases is driving higher demand for gene and cell therapies. This growth is further supported by a rising number of clinical studies, expanded funding opportunities for gene therapy development, and the potential applications of innovative drug delivery methods.

Key Trends Driving Market Growth

1. Rising Incidence of Genetic Disorders and Infectious DiseasesThe increasing prevalence of genetic disorders and infectious diseases has led to a surge in demand for gene and cell therapies, which rely on viral vectors for delivery. This trend is expected to continue, driving the growth of the viral vector manufacturing market.
2. Advancements in Gene and Cell Therapy DevelopmentSignificant progress in gene and cell therapy research has expanded the therapeutic applications of viral vectors. Innovations in vector design and production technologies have improved the safety and efficacy of these therapies, making them more accessible and effective for a broader range of diseases.
3. Increased Funding and Strategic CollaborationsThe market has witnessed a rise in funding opportunities and strategic collaborations aimed at advancing gene therapy development. These investments are facilitating the establishment of new manufacturing facilities and the expansion of existing ones, thereby enhancing production capacities to meet the growing demand.

Market Segmentation

The viral vector manufacturing market is segmented based on type, disease, application, and geography:

• By Type:
  • Adenoviral Vectors: Commonly used due to their high transduction efficiency and ability to accommodate large genetic payloads.
  • Adeno-associated Viral Vectors: Preferred for their safety profile and long-term gene expression capabilities.
  • Lentiviral Vectors: Utilized for their ability to integrate into the host genome, enabling stable gene expression.
  • Retroviral Vectors: Employed in applications requiring permanent gene integration.
  • Other Types: Includes vectors like herpes simplex virus and vaccinia virus, used in specialized applications.
• By Disease:
  • Cancer: Viral vectors are instrumental in developing oncolytic virotherapies and cancer vaccines.
  • Genetic Disorders: Vectors facilitate the correction of genetic mutations through gene therapy.
  • Infectious Diseases: Used in creating vaccines and therapeutic agents against viral infections.
  • Other Diseases: Includes applications in cardiovascular and neurological disorders.
• By Application:
  • Gene Therapy: Involves the delivery of therapeutic genes to treat diseases at the genetic level.
  • Vaccinology: Development of vaccines utilizing viral vectors to elicit immune responses.
• By Geography:
  • North America: Currently holds the largest market share, driven by advanced healthcare infrastructure and significant investments in gene therapy research.
  • Europe: Exhibits substantial growth due to supportive regulatory frameworks and increasing adoption of advanced therapies.
  • Asia-Pacific: Expected to witness the fastest growth, attributed to rising healthcare investments and a growing focus on biotechnology advancements.
  • Middle East & Africa: Gradual growth with improving healthcare facilities and increasing focus on non-communicable diseases.
  • South America: Emerging market with potential growth opportunities due to increasing healthcare access and economic development.

Get a Customized Report Tailored to Your Requirements: https://www.mordorintelligence.com/market-analysis/contract-manufacturers-organizations

Key Players

The viral vector manufacturing market features several prominent companies contributing to its growth:

• Fujifilm Diosynth Biotechnologies: Offers comprehensive viral vector manufacturing services, including process development and cGMP production.
• SIRION Biotech: Specializes in custom viral vector development for gene therapy and vaccine applications.
• Thermo Fisher Scientific: Provides a broad range of viral vector manufacturing solutions, leveraging extensive expertise in bioprocessing.
• Merck KGaA Inc.: Engages in the production of viral vectors, focusing on scalability and regulatory compliance.
• Cognate BioServices Inc. (Cobra Biologics): Offers viral vector development and manufacturing services, supporting various stages from clinical to commercial supply.

These companies are actively engaged in research and development to introduce innovative viral vector products and expand their market presence globally.

Conclusion

The global viral vector manufacturing market is on a robust growth trajectory, projected to reach USD 7.66 billion by 2030. This expansion is fueled by the increasing prevalence of genetic disorders, cancers, and infectious diseases, coupled with advancements in gene and cell therapy development. As key industry players continue to innovate and address the evolving needs of healthcare providers and patients, the viral vector manufacturing market is expected to experience sustained growth, offering significant opportunities for stakeholders.

Industry Related Reports:

Viral Vectors and Plasmid DNA Manufacturing Market: The report highlights Global Plasmid DNA Manufacturing Companies and segments the market by product type, including Plasmid DNA, Viral Vectors, and Non-Viral Vectors. It further categorizes the market by application, covering Cancer, Genetic Disorders, Infectious Diseases, and Other Applications, as well as by geography, spanning North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

ADENO Associated Virus Vectors Manufacturing Market: The Adeno-Associated Virus (AAV) Vectors Manufacturing Market report is segmented by scale of operations, including Clinical and Commercial; by therapeutic area, covering Hematological Diseases, Infectious Diseases, Genetic Disorders, Neurological Disorders, and Others; by application, such as Cell and Gene Therapy and Vaccines; and by geography, spanning North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.

Viral Vector Contract Development and Manufacturing Organization CDMO Market: The Viral Vector Contract Development and Manufacturing Organization (CDMO) Market report is segmented by vector type, including Adenovirus, Retrovirus, Adeno-Associated Virus, Lentivirus, and Others; by workflow, encompassing Upstream Manufacturing and Downstream Manufacturing; by application, covering Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, and Other Applications; by end user, such as Pharmaceutical & Biopharmaceutical Companies and Research Institutes; and by geography, spanning North America, Europe, Asia-Pacific, the Middle East & Africa, and South America.